Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover
Wins Three-Horse Race With Sanofi And J&J
Executive Summary
The US major has announced its biggest acquisition to date in the form of a takeover that should expand its rare disease franchise and stave off concerns about internal products facing biosimilar competition.
You may also be interested in...
Amgen Sees Strong Q4 Growth Even Without Horizon Contribution
The company increased its full-year guidance in anticipation of Horizon’s Q4 contribution and sales for the quarter jumped 20%, but even excluding those drugs product sales were up 5%.
ArriVent Is Second Positive IPO Of 2024 After CG Oncology’s Debut
ArriVent launched the second biopharma initial public offering of 2024, closing above its IPO price on its first day and grossing $175m – and keeping the financial market mood optimistic.
Amgen Absorbs Horizon, Pitches Plans For New Rare Disease Growth Engine
Now that Amgen has completed its $27.8bn acquisition of Horizon, the company can focus on how it will turn Tepezza back into a growth product and maintain momentum for Krystexxa and other assets.